FDA Grants RMAT Designation to CD19 CAR T-Cell Therapy for Stiff Person Syndrome

Retrieved on: 2024-07-16 15:08:49

Tags for this article:

Click the tags to see associated articles and topics

FDA Grants RMAT Designation to CD19 CAR T-Cell Therapy for Stiff Person Syndrome. View article details on hiswai:

Excerpt

The FDA has granted Regenerative Medicine Advanced Therapy designation to KYV-101 for the treatment of refractory stiff person syndrome.

Article found on: www.empr.com